Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

The prevalence and burden of interstitial lung diseases in the USA

Niranjan Jeganathan, Matheni Sathananthan
ERJ Open Research 2022 8: 00630-2021; DOI: 10.1183/23120541.00630-2021
Niranjan Jeganathan
1Dept of Medicine, Division of Pulmonary, Critical Care, Hyperbaric, Allergy and Sleep Medicine, Loma Linda University Health, Loma Linda, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Niranjan Jeganathan
  • For correspondence: njeganathan@llu.edu
Matheni Sathananthan
2Dept of Medicine, Loma Linda University Health, Loma Linda, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Interstitial lung diseases (ILDs) are a significant contributor to disability and deaths in the USA. The prevalence and deaths from ILDs have increased but when adjusted for age, have been stable since 2010. https://bit.ly/3IDlZrg

To the Editor:

Interstitial lung diseases (ILDs) are a heterogeneous group of diseases (i.e. idiopathic interstitial pneumonias, autoimmune ILDs, environmental exposure-related ILDs, sarcoidosis) but share several common clinical and pathophysiological features [1, 2]. ILDs are associated with significant morbidity, mortality and increased financial burden [3, 4].

In the past two decades, there has been significant progress in the diagnosis and treatment of ILDs. However, comprehensive epidemiological data remains limited. Since mortality rates do not give a complete picture of the burden of disease, the World Health Organization assesses the overall burden of disease using disability-adjusted life years (DALYs), a time-based measure that combines years of life lost due to premature mortality and years of healthy life lost due to disability. The objective of this study is to report current estimates and trends of ILD prevalence, DALYs and deaths in the USA.

The data for this study was derived from the Global Burden of Disease (GBD) 2019 study published by the Institute for Health Metrics and Evaluation. The methods used in this study have previously been reported in detail [5]. In brief, the GBD study analyses epidemiologic data using statistical modelling and provides estimates of disease prevalence and burden.

This research study is a secondary analysis of the GBD study results. Data were obtained from the Global Health Data Exchange GBD results online tool [6]. The abbreviation ILD used in our study refers to combined data of both ILDs and pulmonary sarcoidosis. We extracted the crude and age-standardised rates from 2010 to 2019 stratified by sex and age group. Age-standardised rates were based on the GBD global reference population.

In 2019, in the USA, there was an estimated 654 841 (95% uncertainty interval (UI) 566 536–745 855) cases of ILDs, 429 786 (95% UI 283 468–505 372) DALYs and 21 505 (95% UI 12 237–26 667) deaths from ILDs.

In 2019, the crude prevalence of ILDs per 100 000 was 179.7 in males and 218.9 in females (table 1). The age-standardised prevalence of ILDs per 100 000 was 121.3 (95% UI 105.7–136.5) in males and 131.4 (95% UI 114.8–148.3) in females. The overall crude prevalence increased 19.1% from 2010 to 2019, however, the age-standardised prevalence rate was stable.

View this table:
  • View inline
  • View popup
TABLE 1

Prevalence, disability-adjusted life years (DALYs) and mortality rates due to interstitial lung diseases in the USA

In 2019, the crude DALYs from ILDs per 100 000 was 142.4 in males and 118.2 in females. The age-standardised DALYs from ILDs per 100 000 was 93.3 (95% UI 58.9–110.3) in males and 69.3 (95% UI 45.1–82.2) in females. The overall crude DALYs rate increased 15.8% from 2010 to 2019 (21% in males and 10.2% in females). The age-standardised DALYs rate have been stable since 2010.

In 2019, the crude deaths from ILDs per 100 000 was 7.3 in males and 5.9 in females. The age-standardised deaths from ILDs per 100 000 was 4.6 (95% UI 2.5–5.7) in males and 2.9 (95% UI 1.5–3.6) in females. The crude death rates increased 18.1% compared to 2010. The percent increase was higher in males compared to females (25.7% versus 10.2%). The age-standardised death rates were stable.

In 2019, the crude and age-standardised case fatality rates in males were 4.0% (95% UI 2.6–4.4) and 3.8% (95% UI 2.4–4.2), respectively. In females, the crude and age-standardised case fatality rates were 2.7% (95% UI 1.5–3.0) and 2.2% (95% UI 1.3–2.5), respectively.

The age-specific prevalence of ILDs was noted to increase with increasing age, reaching the highest prevalence in the 80–84 years age group. In 2019, the prevalence in this age group per 100 000 in males was 1167 and in females was 983.5. The prevalence of ILDs was slightly lower in males until age 75 years and was higher compared to females in those over age 75 years. The age-specific DALYs rates and death rates also increased with increasing age in both males and females. However, the increase in DALYs rates and death rates were proportionally higher in males compared to females and therefore the difference widened with increasing age (data not shown).

In this study we provide a comprehensive report of the overall prevalence, burden and trends of ILDs in the USA. Our study shows that ILDs remain a significant cause of death and disability in the USA. In 2019, ILDs were present in 0.21% of the population and contributed to 0.39% of the total DALYs and 0.73% of the total deaths. Since 2010 the crude prevalence, DALY rates and death rates of ILDs in the USA have been increasing, but the age-standardised rates have been stable. Crude rates are reflective of the present disease state and are useful for policymakers and physicians, whereas age-standardised estimates allow comparison over time, adjusting for the differences in the age distribution of the population. This finding suggests that the increase in overall prevalence is primarily due to the increasing average age in the US population. Since smoking is a risk factor for idiopathic pulmonary fibrosis (IPF) and several other ILDs, the decline in smoking rates in the USA likely played a significant role in the stable age-standardised prevalence that was noted [8].

In our study, when stratified by age and gender, the prevalence of ILDs was similar for males and females until age 75 years. However, in those older than age 75 years, the prevalence trended toward higher rates in males than females. In addition, the DALYs and deaths seem to increase at a proportionally higher rate for males compared to females over the age of 65 years. This is likely due to a higher percentage of IPF patients among the older age group of patients with ILDs [9, 10]. In 2019, according to the US Centers for Disease Control and Prevention Wonder Underlying Cause of Death Database [11], the crude mortality rate from pulmonary fibrosis per 100 000 was 5.1 (95% CI 5.0–5.2) in males and 3.7 (95% CI 3.6–3.8) in females. Based on this, pulmonary fibrosis contributed to 69.8% of the deaths from ILDs in males and 62.7% in females. The percentage of ILD decedents with pulmonary fibrosis increased with age and was 59.4%, 74.2% and 79.4% in the 65–74 years age group, 75–84 years age group and those 85 years and older, respectively (data not shown).

The general limitations of the GBD study have been reported previously [7]. The limitations of our study include variability in the case definitions used to report ILDs, leading to potential misdiagnosis and under-diagnosis. The majority of data used to estimate prevalence is derived from hospital records and insurance claims which can be unreliable. Attributable risk factor analysis is not currently available for ILDs in the GBD data. The underlying aetiology of ILDs and stratification based on race are also not available in this data set.

This study provides comprehensive national estimates of the prevalence, mortality and DALY due to ILDs. Although age-standardised morbidity and mortality from ILDs have remained stable in the USA, the ILD ranking as the cause of death and DALY has worsened. Among the level three causes, ILD was ranked as 54th in DALYs in 2019, 58th in 2010 and 74th in 1990. Similarly, ILD was ranked 30th among causes of deaths in 2019, compared to 32nd in 2010 and 41st in 1990 [6]. This suggests that the allocation of resources to understand the risk factors for ILDs and to address the burden of disease remains inadequate. Increasing the awareness of the disease, expanding the availability of diagnostic equipment in less-developed areas and improving access to ILD specialised centres are crucial for early diagnosis and intervention.

Footnotes

  • Provenance: Submitted article, peer reviewed.

  • Conflict of interest: N. Jeganathan has nothing to disclose.

  • Conflict of interest: M. Sathananthan has nothing to disclose.

  • Received September 3, 2021.
  • Accepted November 21, 2021.
  • Copyright ©The authors 2022
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org

References

  1. ↵
    1. Cottin V,
    2. Hirani NA,
    3. Hotchkin DL, et al.
    Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev 2018; 27: 180076. doi:10.1183/16000617.0076-2018
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Cottin V,
    2. Wollin L,
    3. Fischer A, et al.
    Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev 2019; 28: 180100. doi:10.1183/16000617.0100-2018
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Frank AL,
    2. Kreuter M,
    3. Schwarzkopf L
    . Economic burden of incident interstitial lung disease (ILD) and the impact of comorbidity on costs of care. Respir Med 2019; 152: 25–31. doi:10.1016/j.rmed.2019.04.009
    OpenUrl
  4. ↵
    1. Fan Y,
    2. Bender SD
    3. Conoscenti CS, et al.
    Hospital-based resource use and costs among patients with idiopathic pulmonary fibrosis enrolled in the idiopathic pulmonary fibrosis prospective outcomes (IPF-PRO) registry. Chest 2020; 157: 1522–1530. doi:10.1016/j.chest.2019.12.041
    OpenUrl
  5. ↵
    1. GBD Chronic Respiratory Disease Collaborators
    . Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med 2020; 8: 585–596. doi:10.1016/S2213-2600(20)30105-3
    OpenUrl
  6. ↵
    1. Global Health Data Exchange
    . GBD results tool. http://ghdx.healthdata.org/gbd-results-tool
  7. ↵
    1. GBD 2019 Diseases and Injuries Collaborators
    . Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396: 1204–1222. doi:10.1016/S0140-6736(20)30925-9
    OpenUrlCrossRefPubMed
  8. ↵
    1. Wang TW,
    2. Asman K,
    3. Gentzke AS, et al.
    Tobacco product use among adults United States, 2017. MMWR Morb Mortal Wkly Rep 2018; 67: 1225–1232. doi:10.15585/mmwr.mm6744a2
    OpenUrlCrossRefPubMed
  9. ↵
    1. Fernandez Perez ER
    . Changing trends in age-adjusted pulmonary fibrosis mortality in the USA: a joinpoint regression analysis. Eur Respir J 2019; 54: 1900364. doi:10.1183/13993003.00364-2019
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Jeganathan N,
    2. Smith RA,
    3. Sathananthan M
    . Mortality trends of idiopathic pulmonary fibrosis in the United States from 2004 through 2017. Chest 2021; 159: 228–238. doi:10.1016/j.chest.2020.08.016
    OpenUrlPubMed
  11. ↵
    1. Centers for Disease Control and Prevention
    Wide-Ranging Online Data for Epidemiologic Research. Underlying Cause of Death, 1999–2019. https://wonder.cdc.gov/ucd-icd10.html. Date last accessed: 25 June, 2021.
PreviousNext
Back to top
Vol 8 Issue 1 Table of Contents
ERJ Open Research: 8 (1)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The prevalence and burden of interstitial lung diseases in the USA
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
The prevalence and burden of interstitial lung diseases in the USA
Niranjan Jeganathan, Matheni Sathananthan
ERJ Open Research Jan 2022, 8 (1) 00630-2021; DOI: 10.1183/23120541.00630-2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The prevalence and burden of interstitial lung diseases in the USA
Niranjan Jeganathan, Matheni Sathananthan
ERJ Open Research Jan 2022, 8 (1) 00630-2021; DOI: 10.1183/23120541.00630-2021
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Interstitial and orphan lung disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Streptococcus pneumoniae re-emerges as a cause of community-acquired pneumonia, including frequent co-infection with SARS-CoV-2, in Germany, 2021
  • Benefit−risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis
  • The use of digital web-based video training for correct inhalation technique during the COVID-19 pandemic
Show more Research letter

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2023 by the European Respiratory Society